HighTide Therapeutics, Inc. (HIGHTIDE-B) submitted its Monthly Return for the period ended 31 March 2026, confirming that both authorised and issued share capital were unchanged during the month.

Authorised Share Capital • Authorised shares remained at 1.00 billion ordinary shares with a par value of USD 0.0001, keeping total authorised share capital at USD 100,000.

Issued Shares • Issued ordinary shares (excluding treasury shares) stood flat at 571.33 million. • The company held no treasury shares, leaving total issued shares likewise at 571.33 million.

Public Float Status • HighTide Therapeutics affirmed compliance with the Main Board’s minimum public-float requirement of 25 % of total issued shares.

Corporate Actions • No activity was recorded under share option schemes, warrants, convertibles, or other equity-linked agreements.

The filing, signed by Executive Director and CEO Dr. Liu Liping, indicates no equity movements or capital structure changes for the reporting month.